Hosted on MSN11mon
FDA approves Madrigal’s Rezdiffra as the first NASH therapyMadrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...
Hosted on MSN11mon
FDA approves first drug for common form of liver inflammationThe new medication, Madrigal Pharmaceuticals’ resmetirom ... and Madrigal must complete a post-approval study to verify the drug’s clinical benefit. “I believe this approval milestone ...
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffraâ„¢ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression ...
Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist. Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback